Insights into GLP-1 and insulin secretion mechanisms in pasireotide-induced hyperglycemia highlight effectiveness of Gs-targeting diabetes treatment
Reported by Nature. Read the original →
The headline reports on research that provides insights into the mechanisms of GLP-1 and insulin secretion related to hyperglycemia induced by pasireotide. It suggests that these insights may highlight the effectiveness of diabetes treatments that target Gs pathways.
Summarised by a model from Nature's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
- Phase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese Adults.Human · RCT · 2026
- Reduced breakthrough symptom exacerbations in patients with biochemically controlled acromegaly switched from injected depot somatostatin receptor ligands to once-daily oral paltusotine in the PATHFNDR-1 clinical trial.Human · RCT · 2026
- Pharmacokinetics and Safety of Long-Acting Release Formulations of Pasireotide (SOM230) in a Male Population Who Are Hyperendemic Hepatitis B/C and Chronic Kidney Disease: An Open-Label, Phase I Study.Human · RCT · 2023
14 compounds tracked · 344 studies on file · 150 in humans
What the headline doesn't tell you
- Pasireotide has 29 studies on file, 17 of them in humans, the newest published 2026.
- This story is about a class — GLP-1 and incretin therapies — rather than one compound. We track 14 compounds in it, holding 344 studies between them, 150 in humans.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.